{"id":"NCT04161495","sponsor":"Bioverativ, a Sanofi company","briefTitle":"A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A","officialTitle":"A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients â‰¥12 Years of Age With Severe Hemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-19","primaryCompletion":"2022-02-03","completion":"2022-02-03","firstPosted":"2019-11-13","resultsPosted":"2023-05-24","lastUpdate":"2023-05-24"},"enrollment":159,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Factor VIII Deficiency"],"interventions":[{"type":"BIOLOGICAL","name":"efanesoctocog alfa (BIVV001)","otherNames":[]}],"arms":[{"label":"Arm A: Prophylaxis","type":"EXPERIMENTAL"},{"label":"Arm B: On-Demand Then Prophylaxis","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\n\\- To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm.\n\nSecondary Objectives:\n\n* To evaluate the efficacy of BIVV001 as a prophylaxis treatment.\n* To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes.\n* To evaluate BIVV001 consumption for the prevention and treatment of bleeding episodes.\n* To evaluate the effect of BIVV001 prophylaxis on joint health outcomes.\n* To evaluate the effect of BIVV001 prophylaxis on Quality of Life outcomes.\n* To evaluate the efficacy of BIVV001 for perioperative management.\n* To evaluate the safety and tolerability of BIVV001 treatment.\n* To assess the pharmacokinetics (PK) of BIVV001 based on the 1-stage activated partial thromboplastin time (aPTT) and 2-stage chromogenic coagulation factor VIII (FVIII) activity assays.","primaryOutcome":{"measure":"Estimated Annualized Bleeding Rate (ABR) in Arm A: Prophylaxis","timeFrame":"Baseline to Week 52","effectByArm":[{"arm":"Arm A: Prophylaxis","deltaMin":0.71,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":47,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","France","Germany","Greece","Hungary","Italy","Japan","Mexico","Netherlands","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["40099428","39927501","39414418","36720133"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":133},"commonTop":["Headache","Arthralgia","Fall","Back Pain","Fatigue"]}}